Home » Stocks » DRIO

DarioHealth Corp. (DRIO)

Stock Price: $18.09 USD -0.78 (-4.13%)
Updated May 6, 2021 4:00 PM EDT - Market closed
Market Cap 292.02M
Revenue (ttm) 7.58M
Net Income (ttm) -33.10M
Shares Out 15.48M
EPS (ttm) -5.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $18.09
Previous Close $18.87
Change ($) -0.78
Change (%) -4.13%
Day's Open 18.78
Day's Range 17.42 - 19.14
Day's Volume 159,300
52-Week Range 5.55 - 31.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, April 20, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of a new virtual care initiative with MediOrbis...

2 weeks ago - PRNewsWire

NEW YORK, March 9, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the fourth quarter and full year 2020 ...

1 month ago - PRNewsWire

DarioHealth (NASDAQ:DRIO) releases its next round of earnings this Tuesday, March 09. Here is Benzinga's essential guide to DarioHealth's Q4 earnings report.

1 month ago - Benzinga

NEW YORK, March 1, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it would release its financial results for the fourth quart...

2 months ago - PRNewsWire

NEW YORK, Feb. 19, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that Erez Raphael, Chief Executive Officer, is schedu...

2 months ago - PRNewsWire

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today the signing of a definitive agreement to acquire digi...

3 months ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of DarioHealth Corp. (Nasdaq: DRIO) concerning the Company and its directors' and officers' possible ...

3 months ago - Business Wire

NEW YORK, Dec. 22, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the Company has entered into an agreement to pro...

4 months ago - PRNewsWire

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the third quarter 2020 and provided a ...

5 months ago - PRNewsWire

DRIO offers a diabetes management solution that is highly rated, provides strong ROI for all parties, and simpler than main competitor Livongo. Seasoned executives in the digital therapeutics space have...

6 months ago - Seeking Alpha

NEW YORK, Oct. 13, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced that Vitality Group has chosen the company's digital therapeutics...

6 months ago - PRNewsWire

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of DarioHealth (NASDAQ:DRIO) moved higher by 2% in pre-market trading after the company reported Q2 results.

8 months ago - Benzinga

NEW YORK, Aug. 12, 2020 /PRNewswire/ -- DarioHealth Corp.

8 months ago - PRNewsWire

NEW YORK, July 31, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it closed a private placement transaction with accredi...

9 months ago - PRNewsWire

NEW YORK, June 11, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that the company has signed its first two remote patient mo...

10 months ago - PRNewsWire

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Shares of DarioHealth (NASDAQ:DRIO) remained unaffected at $7.95 after the company reported Q1 results.

11 months ago - Benzinga

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Shares of digital health company DarioHealth Corp (NASDAQ: DRIO) are advancing strongly Tuesday.

1 year ago - Benzinga

Shares of DarioHealth Corp. DRIO, +23.40% jumped 103% as it announced that Walmart would sell DarioHealth's digital diabetes management system online.

1 year ago - Market Watch

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

DarioHealth's (DRIO) CEO Erez Raphael on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

DarioHealth's (DRIO) CEO Erez Raphael on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

DarioHealth Corp. (DRIO) CEO Erez Raphael on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About DRIO

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic ... [Read more...]

Industry
Diagnostics & Research
Founded
2011
Stock Exchange
NASDAQ
Ticker Symbol
DRIO
Full Company Profile

Financial Performance

In 2020, DarioHealth's revenue was $7.58 million, an increase of 0.22% compared to the previous year's $7.56 million. Losses were -$29.45 million, 66.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for DarioHealth stock is "Strong Buy." The 12-month stock price forecast is 29.28, which is an increase of 61.86% from the latest price.

Price Target
$29.28
(61.86% upside)
Analyst Consensus: Strong Buy